1. Introduction

Alzheimer’s genomic screening employment discrimination refers to the legal and ethical problems that arise when an employer uses an employee’s or job applicant’s genetic information associated with Alzheimer’s disease to make decisions about recruitment, promotion, job allocation, dismissal, workplace benefits, or continued employment.

Alzheimer’s disease is a progressive neurological disorder that affects memory, thinking, and behaviour. Certain genetic variants, including variants of the APOE gene, are associated with an increased risk of developing Alzheimer’s disease. However, possessing a risk-associated variant does not establish that a person currently has Alzheimer’s disease or will inevitably develop it.

This distinction is fundamental to employment law: a genetic predisposition is not the same as a present disability or an inability to perform a job.

For example, suppose an employer requires a 35-year-old applicant to undergo genetic screening and discovers that the applicant carries a variant associated with increased Alzheimer’s risk. The employer then refuses to hire the applicant because it anticipates future cognitive impairment. Such conduct may constitute genetic discrimination under applicable law.

The legal framework differs between countries. In the United States, the Genetic Information Nondiscrimination Act of 2008 (GINA) provides a specific statutory framework. In India, the United Kingdom, Australia, and other jurisdictions, the analysis depends on privacy, disability, equality, employment, and medical-information laws.

This explanation examines the principal legal principles and judicial decisions, with particular emphasis on the United States and additional comparative analysis relevant to India.

2. Meaning and scope of Alzheimer’s genomic screening

Genomic screening involves examining genetic material to identify variants associated with a disease, a disease predisposition, or a biological characteristic.

In the Alzheimer’s employment context, screening may involve:

Testing for genetic variants associated with increased Alzheimer’s risk.

Examining family medical history of Alzheimer’s disease or other forms of dementia.

Using genetic information to estimate future cognitive decline.

Combining genomic information with biomarkers, medical records, or predictive algorithms.

Using genetic or health-related predictions in recruitment, occupational health assessments, promotion, or dismissal.

Three situations must be distinguished.

Genetic screening should not be confused with a clinically justified assessment of a person's present functional capacity. The latter may be lawful in some circumstances, subject to the applicable legal safeguards.

3. Legal framework in the United States

A. Genetic Information Nondiscrimination Act, 2008 (GINA)

The principal United States statute is the Genetic Information Nondiscrimination Act of 2008. Title II, codified at 42 U.S.C. § 2000ff et seq., regulates genetic discrimination in employment.

Under GINA, covered employers generally cannot use genetic information to make decisions concerning:

Recruitment and selection.

Dismissal, demotion, or disciplinary action.

Promotion and compensation.

Job assignments and training opportunities.

Other terms and conditions of employment.

GINA also restricts employers from requesting, requiring, or purchasing genetic information, subject to narrow statutory exceptions, and imposes confidentiality requirements. The law generally applies to employers with at least 15 employees.

U.S. Equal Employment Opportunity Commission

+2

Application to Alzheimer’s screening

Suppose an employer rejects a qualified applicant because genetic testing suggests that the applicant has a higher probability of developing Alzheimer’s disease in the future.

The legal issues would include:

Whether the employer obtained or used genetic information covered by GINA.

Whether that information influenced the adverse employment decision.

Whether the employer unlawfully requested or required genetic information.

Whether the employer improperly disclosed or retained confidential genetic records.

An employer cannot justify an employment decision merely by claiming that it wishes to avoid future absenteeism, training costs, or anticipated medical expenses. GINA prohibits using genetic information to make employment decisions, even where the employer believes it is acting in the employee’s interests.

U.S. Department of Labor

+1

B. Genetic information versus manifested disease

An important distinction exists between genetic predisposition and an existing medical condition.

GINA’s definition of genetic information includes family medical history and genetic test results. However, it generally excludes information about a disease or disorder that has already manifested in the individual concerned.

Where Alzheimer’s disease has manifested, the Americans with Disabilities Act (ADA) may become relevant if the statutory requirements are satisfied. The ADA also restricts medical inquiries and examinations at different stages of employment.

An employer should therefore distinguish between:

A genetic result indicating possible future risk.

A diagnosis of Alzheimer’s disease.

Evidence of current limitations affecting particular job functions.

A genetic risk result alone is not proof of present incapacity. Conversely, a genuine, present impairment may require a separate assessment under disability law, based on applicable legal standards rather than assumptions about genetics.

C. Restrictions on obtaining genetic information

GINA does not simply prohibit discriminatory decisions; it also regulates how employers acquire genetic information.

For example, an employer generally cannot require an applicant to disclose whether a parent developed Alzheimer’s disease, or require an employee to undergo predictive genetic testing as a condition of continued employment.

Limited exceptions include certain inadvertent acquisitions of genetic information, qualifying voluntary health services, specified leave-related documentation, and other circumstances defined by law. These exceptions do not create a general right to use acquired genetic information in employment decisions.

U.S. Equal Employment Opportunity Commission

+1

4. Important case laws

There is an important qualification: the following cases establish relevant principles of genetic privacy, disability discrimination, medical confidentiality, and constitutional privacy. They are not all direct decisions about Alzheimer’s genomic screening, and no Alzheimer-specific holding should be inferred from them.

Case 1: Norman-Bloodsaw v. Lawrence Berkeley Laboratory

135 F.3d 1260 (9th Cir. 1998)

Facts: Employees of Lawrence Berkeley Laboratory alleged that their employer conducted tests for conditions including sickle-cell trait, syphilis, and pregnancy without their knowledge or consent during employment-related medical examinations.

Legal issue: Whether undisclosed medical testing and the handling of sensitive health information could violate employees’ privacy and civil rights.

Decision: The United States Court of Appeals for the Ninth Circuit reversed the lower court’s disposition of important privacy and Title VII claims, allowing those claims to proceed. It affirmed the dismissal of the ADA claims. The court emphasized that consent to a general medical examination did not necessarily mean consent to undisclosed, highly personal testing.

Justia Law

+1

Relevance to Alzheimer’s genomic screening:

This case is particularly relevant where an employer secretly performs genomic testing or uses a biological sample for an undisclosed purpose.

It supports the proposition that:

Consent to an ordinary medical examination is not automatically consent to every genetic test.

Sensitive medical information attracts substantial privacy protection.

Testing practices may raise separate privacy and discrimination issues.

The case preceded GINA, which was enacted in 2008. It therefore should not be described as a decision applying GINA.

Case 2: Doe v. City of New York

15 F.3d 264 (2d Cir. 1994)

Facts and legal issue: The case concerned confidentiality of sensitive medical information relating to HIV and the disclosure of that information in an employment-related public context.

Decision: The Second Circuit recognized the importance of protecting confidential medical information and addressed the constitutional privacy interests implicated by disclosure.

law.justia.com

+1

Relevance to Alzheimer’s screening:

An employee’s genetic risk information may be deeply personal, particularly where it could lead to stigma or assumptions about future cognitive ability.

The case offers a useful analogy for claims involving unauthorized disclosure of genetic or medical information. However, HIV-related confidentiality law and Alzheimer’s genetic discrimination are not identical legal questions, and the decision does not establish a specific rule about Alzheimer’s testing.

Case 3: Bragdon v. Abbott

524 U.S. 624 (1998)

Principle: The United States Supreme Court examined disability coverage under the ADA in the context of an individual with HIV.

The decision illustrates the importance of applying disability law to the individual's actual circumstances and the relevant statutory definition, rather than relying exclusively on generalized assumptions about a medical condition.

Relevance to Alzheimer’s screening:

The case may assist in understanding disability-law principles where an employee has a diagnosed condition. However, it is not a genetic-screening case and does not establish that an asymptomatic person with an Alzheimer’s-associated genetic variant is disabled under the ADA.

The legal analysis must distinguish genetic susceptibility from a qualifying present disability.

Case 4: School Board of Nassau County v. Arline

480 U.S. 273 (1987)

Principle: The Supreme Court considered disability discrimination and the assessment of risks associated with an individual's medical condition.

Relevance: The decision illustrates why disability-related employment decisions must be evaluated under the governing legal framework rather than based on unsupported generalizations. Its factual setting involved a contagious disease, not genetic predisposition.

In the Alzheimer’s context, the analogy is limited: an employer should not automatically treat a genetic risk marker as evidence that an employee is presently incapable of performing a job. Any assessment of current capacity or safety must comply with the applicable law.

Case 5: Norman-Bloodsaw and the limits of medical consent

Of the cases discussed, Norman-Bloodsaw is the closest factual analogy to compulsory or undisclosed workplace genomic screening. Its importance lies in the separation between a general occupational medical examination and additional testing that reveals highly sensitive information.

A court considering a modern Alzheimer’s screening dispute would still need to examine the applicable statute, the type of testing, the employer's conduct, the consent given, and the employment consequences. The case does not automatically determine the outcome of such a dispute.

5. Legal position in India

India does not have a direct equivalent to the United States’ GINA framework that comprehensively prohibits all employment discrimination based on genetic information. Nevertheless, several constitutional and statutory principles may be relevant.

A. Article 14 of the Constitution of India — Equality before law

Article 14 guarantees equality before the law and equal protection of the laws.

If a public employer rejects an applicant solely because of an Alzheimer’s-associated genetic variant, without a rational and legally defensible connection between that information and the requirements of the post, the decision may be challenged as arbitrary or unreasonable.

Relevant case law:

** E.P. Royappa v. State of Tamil Nadu, (1974) 4 SCC 3**

The Supreme Court developed the principle that arbitrary State action is inconsistent with equality under Article 14.

Application: A government recruitment authority that automatically excludes applicants with a genetic predisposition to Alzheimer’s disease may face an Article 14 challenge, particularly where the applicant has no present impairment and the exclusion is unsupported by job-related evidence.

Limitation: Article 14 primarily governs State action. A claim against a private employer requires identification of an applicable statutory or other legal basis.

B. Article 21 — Privacy, dignity and personal autonomy

Article 21 protects life and personal liberty. Its interpretation includes constitutional protection for privacy and personal autonomy.

** Justice K.S. Puttaswamy (Retd.) v. Union of India, (2017) 10 SCC 1**

The Supreme Court recognized privacy as a fundamental right under the Constitution.

Application to genomic screening may include:

The collection of genetic samples without proper authorization.

Unnecessary collection of genetic information by a public authority.

Disclosure of predictive medical information without lawful justification.

Retention or use of sensitive genetic information in ways that unjustifiably interfere with privacy.

Where a government employer conducts genomic screening, the legality and proportionality of the interference may require examination.

The judgment does not specifically decide employment discrimination based on Alzheimer’s genetic risk. Its privacy principles provide a constitutional foundation for analyzing such conduct.

C. Rights of Persons with Disabilities Act, 2016

Section 20 of the Rights of Persons with Disabilities Act, 2016 addresses non-discrimination in employment by government establishments. Other provisions of the Act may also be relevant where the statutory definition of disability and the applicable requirements are satisfied.

IndiaCode

For Alzheimer’s-related employment disputes, two situations must be separated:

Genetic predisposition without present impairment: The Act should not automatically be assumed to cover every person carrying an Alzheimer’s-associated genetic variant.

Manifested cognitive impairment: The Act may become relevant if the individual satisfies its applicable definition and other statutory conditions.

A public employer should not simply equate a genetic risk marker with an established disability or inability to work.

D. Data protection and medical confidentiality

Genetic information is especially sensitive because it may reveal information not only about the tested person but also about biological relatives.

The collection and processing of genetic information may raise questions under applicable Indian data-protection law, including the Digital Personal Data Protection Act, 2023, to the extent its provisions are in force and applicable to the processing in question. Medical confidentiality and professional obligations may also be relevant.

A legal analysis should determine:

The legal basis for collecting the data.

Whether the stated purpose justifies the collection.

Whether the information is being used for a different purpose.

Who can access the results.

Whether disclosure or retention is lawful.

India's constitutional privacy jurisprudence and employment protections provide relevant arguments, but they should not be presented as an already-established, comprehensive statutory prohibition identical to GINA.

6. Comparative legal position

7. Employer liability: common hypothetical situations

The following examples illustrate how the legal analysis may operate.

Situation A: Rejection based on genetic predisposition

An employer rejects an otherwise qualified applicant after learning that the applicant carries an Alzheimer’s-associated genetic variant.

Potential legal consequence: In the United States, this may violate GINA if the decision was based on protected genetic information. In India, the analysis depends on the applicable legal framework and whether constitutional or statutory protections are engaged.

Situation B: Secret genetic testing

An employer uses blood collected for an ordinary medical examination to conduct an undisclosed genomic test.

Potential legal consequence: This may raise consent, privacy, confidentiality, and genetic-information acquisition issues. Norman-Bloodsaw is a relevant US precedent.

Situation C: Disclosure to colleagues

A manager reveals an employee’s genetic risk information to colleagues, causing stigma or workplace exclusion.

Potential legal consequence: Depending on the facts, this may engage confidentiality, privacy, harassment, and discrimination rules.

Situation D: Genuine present functional limitation

An employee has diagnosed cognitive impairment that may affect a specific safety-critical duty.

Potential legal consequence: A lawful, individualized assessment may be appropriate under the applicable employment and disability framework. The employer should assess actual functional capacity rather than infer incapacity from a genetic result alone.

8. Evidence required to establish a claim

A person alleging Alzheimer’s genomic screening employment discrimination may need evidence of the following matters, depending on the jurisdiction and cause of action.

1. Evidence of genetic testing

Test reports or laboratory records.

Medical examination forms.

Consent forms and notices.

Employer instructions to healthcare providers.

2. Evidence of employer knowledge

Emails or internal correspondence referring to genetic risk.

Recruitment or occupational health records.

Communications between human resources and medical personnel.

Evidence of unauthorized access to genomic information.

3. Evidence of adverse treatment

Rejection letters.

Dismissal or demotion records.

Changes in pay, assignments, or promotion opportunities.

Evidence that similarly situated employees were treated differently.

4. Evidence connecting the information to the decision

A claim may be strengthened by statements showing that the employer acted because of the applicant’s genetic profile rather than a legitimate, independently established factor.

5. Evidence of privacy violations

Proof of undisclosed testing.

Records of unauthorized disclosure.

Evidence of improper retention or access.

The scope of consent originally provided.

The exact burden of proof, disclosure rules, limitation periods, and available remedies depend on the particular claim.

9. Remedies and enforcement

United States

Potential avenues include:

Filing a genetic-discrimination charge with the Equal Employment Opportunity Commission (EEOC).

Seeking appropriate relief for unlawful employment decisions.

Pursuing available remedies for unlawful acquisition or disclosure of genetic information.

Bringing additional claims where independent privacy, disability, or other legal violations are established.

Under EEOC guidance, the usual charge-filing period is 180 days, extended to 300 days in certain circumstances where a qualifying state or local agency enforces a relevant prohibition. The applicable deadline should be verified promptly.

U.S. Equal Employment Opportunity Commission

+1

India

Depending on the facts, potential avenues may include:

A constitutional challenge to arbitrary State-employer action.

Appropriate employment or service-law proceedings.

Complaints or proceedings under applicable disability legislation.

Remedies available under applicable data-protection, privacy, confidentiality, or other laws.

The availability of a remedy depends on the employer's status, the legal relationship, the nature of the alleged violation, and the legislation applicable at the relevant time.

10. Ethical and regulatory considerations

Alzheimer’s genomic screening creates several problems that extend beyond conventional employment discrimination.

Predictive uncertainty: A risk-associated genetic variant does not reliably establish when, whether, or how severely a person may develop a disease.

Scientific validity: Different genetic tests and prediction models have different evidentiary limitations. Employers should not treat a probabilistic prediction as a definitive diagnosis.

Genetic privacy: Genetic information can reveal familial information and create privacy risks beyond those associated with ordinary occupational assessments.

Algorithmic discrimination: If employers use AI systems to rank applicants according to genetic information or predicted future medical costs, the system may reproduce or amplify discriminatory practices. Automated decision-making does not remove the employer's legal responsibilities.

Proportionality and job relevance: Where a genuine present functional limitation is relevant to a particular role, assessment should be grounded in the actual job requirements and applicable law—not speculative assumptions about future illness.

11. Conclusion

Alzheimer’s genomic screening employment discrimination concerns the conflict between employers’ interest in managing workforce risks and individuals’ rights to equality, privacy, dignity, and fair employment.

In the United States, GINA provides the clearest specific statutory protection against employment decisions based on genetic information, while the ADA may become relevant where an individual has a qualifying manifested disability. Norman-Bloodsaw v. Lawrence Berkeley Laboratory is a particularly useful precedent concerning undisclosed workplace medical and genetic testing.

In India, Justice K.S. Puttaswamy v. Union of India and E.P. Royappa v. State of Tamil Nadu provide important constitutional principles concerning privacy and non-arbitrariness. The Rights of Persons with Disabilities Act, 2016, may also apply in appropriate cases. However, these authorities should not be mistaken for a direct judicial ruling that comprehensively prohibits all employment discrimination based on Alzheimer’s genetic predisposition.

The central legal principle is that an employer should not treat a probabilistic genetic risk as proof of present incapacity. The legality of any screening, employment decision, or disclosure must be assessed under the governing jurisdiction's rules on genetic information, privacy, disability, equality, and employment.